Other languages Verastem, Inc.

Equities

VSTM

US92337C2035

Real-time Estimate Cboe BZX Other stock markets 09:11:59 29/04/2024 pm IST			5-day change	1st Jan Change
9.535 ^USD	+1.65%		-0.82%	+18.67%

18/04	Verastem Names John Hayslip as Chief Medical Officer	MT
18/04	Verastem Oncology Announces Executive Changes	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Verastem Oncology Announces Executive Changes	19/04
Verastem, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/03
Verastem, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	15/03
Verastem Gets Orphan Drug Designation From US FDA for Avutometinib to Treat Type of Ovarian Cancer	06/03
Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Broader Pipeline in RAS Pathway-Driven Cancers	29/01
Sector Update: Health Care Stocks Mixed Premarket Friday	19/01
Sector Update: Health Care	19/01
Verastem Gets Fast Track Label For Avutometinib Combination in Non-Small Cell Lung Cancer	19/01
Verastem Oncology Selects Oral Kras G12d Inhibitor Gfh375/Vs-7375 as Lead Program in Discovery and Development Collaboration with Genfleet Therapeutics	18/12
Verastem Starts Confirmatory Trial of Ovarian Cancer Treatment Candidate	14/12
Verastem Oncology Announces Initiation of A Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer	13/12
Verastem Oncology Announces the Launch of the New Healthcare Professional Component	13/11
Verastem, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
Verastem Promotes Vice President of Finance Dan Calkins to CFO	28/23/28
Verastem Oncology Announces Executive Appointments	27/23/27
Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS? in KRAS G12C-Mutant Non-Small Cell Lung Cancer	14/23/14
Verastem Partners With GenFleet Therapeutics to Advance Oncology Discovery Programs	28/23/28
Verastem Oncology Enters Discovery and Development Collaboration with GenFleet Therapeutics to Advance New Programs Targeting Ras Pathway-Driven Cancers	28/23/28
Verastem, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09
Verastem, Inc. Appoints Daniel Paterson as Class III Director	12/23/12

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Verastem, Inc.

Equities

VSTM

US92337C2035

Other languages

Filters